CRL up +1.22% percent right now. $CRL High is at 64.80 and the Low 63.92 with current volume of 90,042.
Recent News posted below.
CRL Charles River Laboratories Intl Recent Headline News
Regulatory Affairs Outsourcing Market - Global Industry Analysis 2014 - 2020
M2 - Tue Nov 11, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/8t6h79/regulatory) has announced the addition of the "Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global regulatory affairs outsourcing market is segmented by services into regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others (post approval maintenance, reimbursement consulting etc.). Regulatory writing and publishing services accounted for the largest share of more than 40% of the overall regulatory affairs outsourcing market in 2013 and is expected to maintain its lead during the forecast period through 2014 to 2020. Factors that have contributed towards the large market size of the regulatory writing and publishing services are increasing need for user/reviewer friendly and complete drug application submissions, and sound knowledge for drug development services. Additionally, a well-written clinical study report (CSR) can help in adding a lot of value in the final production of clinical trial documentation, thereby complying with stringent regulatory requirements of the drug development process. The regulatory consulting and legal representation services segment is also estimated to grow at an approximate CAGR of above 14%. The major driving factors for the rapid growth of this segment are growing demand of drug manufacturing companies for product safety and efficacy evaluations. Furthermore, the need of various pharmaceutical companies to minimize business impacts such as product recalls and loss of sales, and ensure global environmental compliance would also propel the growth of the regulatory consulting and legal representation services segment. Currently, the regulatory affairs outsourcing market is fragmented due to the involvement of several established and emerging contract research organizations. Some of the major players operating in the global regulatory affairs outsourcing market are Charles River Laboratories International, Inc., Covance Group Ltd., Parexel International Corporation, WuXi AppTec, Quintiles Transnational Holdings, Inc., Medpace, Inc., Promedica International, Clinilabs, Inc., Accell Clinical Research, LLC, Criterium, Inc., ICON plc and Pharmaceutical Product Development. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Regulatory Affairs Outsourcing Market Overview Chapter 4 Global Regulatory Affairs Outsourcing Market, by Services Chapter 5 Global Regulatory Affairs Outsourcing Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Accell Clinical Research, LLC - Charles River Laboratories International, Inc. - Clinilabs, Inc. - Covance, Inc. - Criterium, Inc. - ICON plc - Medpace, Inc. - PAREXEL International Corporation - PRA International, Inc. - Pharmaceutical Product Development, LLC - Promedica International - Quintiles Transnational Corporation - WuXi AppTec For more information visit http://www.researchandmarkets.com/research/8t6h79/regulatory
PRXL: 54.78 (+0.28), CRL: 64.08 (+0.15), ICLR: 53.37 (+0.03), CVD: 100.42 (-0.45)
Charles River Laboratories Earnings In Retrospect: Down 1.7% in the Last 12 Days (CRL)
Comtex SmarTrend(R) - Mon Nov 10, 9:16AM CST
A week ago on October 29th, 2014 Charles River Laboratories (NYSE:CRL) reported earnings and analysts, on average, expected earnings of $0.80 on sales of $326.8 million. The company actually reported EPS of $0.86 on sales of $327.6 million, beating EPS estimates by $0.06 and beating revenue estimates by $0.8 million. Shares of Charles River Laboratories have slipped from $64.47 to $63.36, representing a loss of 1.7%, since the company reported earnings 12 days ago.
CRL: 64.08 (+0.15)
Strength Seen in Covance (CVD): Stock Surges 25.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:25AM CST
Covance (CVD) was a big mover last session, with shares surging nearly 26% on the day.
BEAT: 8.22 (+0.02), CRL: 64.08 (+0.15), ICLR: 53.37 (+0.03), CVD: 100.42 (-0.45)
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 10.93 (+0.19), TTWO: 26.09 (-0.01), BIIB: 323.95 (-3.92), GILD: 108.47 (+1.45), CRL: 64.08 (+0.15), REGN: 399.36 (+13.39), CELG: 107.55 (-0.46)
Cramer's Mad Money - Charles River Labs Battles Ebola (10/30/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Oct 31, 4:46AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday October 30. CEO Interview: James Foster, Charles River Labs (NYSE: CRL ) Cramer spoke with James Foster, CEO of Charles River Labs ( CRL ). The company...
FLEX: 10.93 (+0.19), MMM: 156.72 (-0.94), BIIB: 323.95 (-3.92), CLR: 54.83 (+0.61), HON: 96.81 (-0.46), FB: 74.36 (-0.64), DIS: 89.76 (-0.02), BMY: 58.69 (-0.12), CELG: 107.55 (-0.46), SBUX: 77.60 (-0.05), WWAV: 36.34 (+0.34), HAIN: 105.58 (-3.63), UA: 68.04 (-0.30), TTWO: 26.09 (-0.01), RDS.B: 74.45 (+0.28), RDS.A: 71.05 (+0.34), TJX: 63.22 (-0.70), GILD: 108.47 (+1.45), CMG: 654.12 (+5.26), COST: 136.69 (-1.00), BP: 41.83 (-0.03), ARCP: 8.67 (+0.17), CRL: 64.08 (+0.15), AAPL: 109.21 (+0.38), REGN: 399.36 (+13.39), WEN: 8.46 (-0.09)
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 156.70 (-0.96), BIIB: 323.95 (-3.92), HON: 96.81 (-0.46), FB: 74.36 (-0.64), BMY: 58.70 (-0.11), MGM: 22.46 (+0.32), ATK: 111.44 (+1.18), YRCW: 24.40 (+0.10), UPS: 108.70 (-0.35), SLB: 98.19 (-0.10), CELG: 107.55 (-0.46), WPRT: 6.11 (+0.23), SBUX: 77.60 (-0.05), TTWO: 26.09 (-0.01), DO: 36.77 (-0.70), ETP: 64.93 (-0.44), GILD: 108.47 (+1.45), ARR: 3.98 (-0.01), CMG: 654.12 (+5.26), MPEL: 25.77 (+0.58), WNC: 10.75 (-0.01), CRL: 64.08 (+0.15), AAPL: 109.21 (+0.38), REGN: 399.36 (+13.39)
Charles River Laboratories International's (CRL) CEO James Foster on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 1:50PM CDT
CRL: 64.08 (+0.15)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 195.66 (+0.42), ABBV: 63.68 (-0.11), BMY: 58.70 (-0.11), CRL: 64.08 (+0.15)
Charles River Laboratories raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 9:53AM CDT
CRL: 64.08 (+0.15)
Charles River Laboratories International In (CRL) Falls Further As It's Water-Logged And Getting Wetter
at The Street - Thu Oct 30, 9:04AM CDT
Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
CRL: 64.08 (+0.15)
Charles River beats Street 3Q forecasts
Automated Insights - Wed Oct 29, 5:45PM CDT
WILMINGTON, Mass. (AP) _ Charles River Laboratories International Inc. (CRL) on Wednesday reported third-quarter earnings of $32 million.
CRL: 64.08 (+0.15)
Ampersand Exits ChanTest Investment
PR Newswire - Wed Oct 29, 3:56PM CDT
Ampersand Capital Partners is pleased to announce the successful sale of Cleveland, Ohio based ChanTest, a leading provider of specialized laboratory testing services for drug development. ChanTest has been acquired by Charles River Laboratories International, Inc. in an all-cash transaction.
CRL: 64.08 (+0.15)
Charles River Laboratories beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:30PM CDT
CRL: 64.08 (+0.15)
Charles River Laboratories Announces Third-Quarter 2014 Results from Continuing Operations
Business Wire - Wed Oct 29, 3:06PM CDT
--- Third-Quarter GAAP Earnings per Share of $0.68 and Non-GAAP Earnings per Share of $0.86 -
CRL: 64.08 (+0.15)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 195.66 (+0.42), ESRX: 77.70 (-0.29), CAH: 79.62 (+0.53), UNH: 95.61 (+0.86), CRL: 64.08 (+0.15)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 195.66 (+0.42), MCK: 202.49 (+1.21), CAH: 79.62 (+0.53), CRL: 64.08 (+0.15)
Will Cigna's (CI) Business Diversity Drive Q3 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:01PM CDT
We expect Cigna (CI) to give a positive surprise when it reports its earnings on Oct 30, given its Zacks Rank #3 and a positive Earnings ESP.
CI: 101.97 (+0.69), INFI: 13.65 (+0.08), AMAG: 34.92 (+0.01), CRL: 64.08 (+0.15)
Will PerkinElmer (PKI) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 4:59PM CDT
PerkinElmer (PKI) has managed to perform decently across several product lines and also posted solid operating results in the previous quarter.
HTWR: 79.14 (+0.53), CRL: 64.08 (+0.15), HSIC: 129.29 (-0.33), PKI: 43.79 (-0.23)
Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:35PM CDT
CSGP: 159.96 (-0.02), CNW: 46.12 (-0.23), ACMP: 62.11 (-0.53), BGC: 13.98 (-0.07), DAC: 6.24 (-0.04), AIZ: 67.73 (-0.27), AEM: 24.16 (+1.15), ESRT: 15.96 (-0.06), CAR: 57.65 (-0.32), CWT: 25.39 (-0.24), AHL: 43.29 (-0.26), CLUB: 6.13 (-0.64), CAVM: 52.44 (-0.16), CJES: 18.86 (-0.06), FB: 74.36 (-0.64), AKAM: 60.98 (-0.09), EXR: 58.50 (-0.15), DWA: 21.89 (-0.20), EXL: 12.92 (-0.10), ANIK: 41.45 (+0.54), CLD: 12.98 (-0.05), ALL: 66.62 (-0.14), DRIV: 24.52 (-0.25), EQIX: 222.21 (+4.18), ESV: 39.39 (-0.53), ASGN: 30.03 (+0.01), AUY: 3.92 (+0.26), ACHC: 61.05 (-0.24), CALX: 11.33 (-0.05), CSII: 29.89 (-0.13), AFOP: 13.70 (unch), ARAY: 7.02 (+0.12), AEGN: 19.46 (-0.36), ATML: 7.56 (-0.04), CENX: 27.41 (+0.09), CUZ: 12.83 (-0.17), CACI: 85.37 (+1.45), ACGL: 57.21 (-0.05), AXS: 49.17 (-0.05), BMR: 21.58 (-0.07), ARII: 68.17 (-0.91), CBG: 32.47 (+0.66), CW: 70.66 (+0.10), DRE: 19.66 (+0.07), ABX: 11.75 (+0.40), CBL: 18.98 (-0.42), CHDN: 104.33 (-0.10), CMO: 12.63 (-0.03), CATM: 38.11 (+0.19), BLKB: 44.19 (-0.56), BIDU: 248.04 (+0.46), EQY: 24.15 (unch), ARRS: 28.69 (-1.77), ALDW: 18.73 (-0.51), CRUS: 19.57 (-0.12), CEMP: 14.13 (+0.33), CRL: 64.08 (+0.15)
Why Earnings Season Could Be Great for Charles River Laboratories International (CRL) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:57AM CDT
Investors are always looking for stocks that are poised to beat at earnings season and Charles River Laboratories International may be one such company as the firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report
CRL: 64.08 (+0.15)
Recent News posted below.
CRL Charles River Laboratories Intl Recent Headline News
Regulatory Affairs Outsourcing Market - Global Industry Analysis 2014 - 2020
M2 - Tue Nov 11, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/8t6h79/regulatory) has announced the addition of the "Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global regulatory affairs outsourcing market is segmented by services into regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others (post approval maintenance, reimbursement consulting etc.). Regulatory writing and publishing services accounted for the largest share of more than 40% of the overall regulatory affairs outsourcing market in 2013 and is expected to maintain its lead during the forecast period through 2014 to 2020. Factors that have contributed towards the large market size of the regulatory writing and publishing services are increasing need for user/reviewer friendly and complete drug application submissions, and sound knowledge for drug development services. Additionally, a well-written clinical study report (CSR) can help in adding a lot of value in the final production of clinical trial documentation, thereby complying with stringent regulatory requirements of the drug development process. The regulatory consulting and legal representation services segment is also estimated to grow at an approximate CAGR of above 14%. The major driving factors for the rapid growth of this segment are growing demand of drug manufacturing companies for product safety and efficacy evaluations. Furthermore, the need of various pharmaceutical companies to minimize business impacts such as product recalls and loss of sales, and ensure global environmental compliance would also propel the growth of the regulatory consulting and legal representation services segment. Currently, the regulatory affairs outsourcing market is fragmented due to the involvement of several established and emerging contract research organizations. Some of the major players operating in the global regulatory affairs outsourcing market are Charles River Laboratories International, Inc., Covance Group Ltd., Parexel International Corporation, WuXi AppTec, Quintiles Transnational Holdings, Inc., Medpace, Inc., Promedica International, Clinilabs, Inc., Accell Clinical Research, LLC, Criterium, Inc., ICON plc and Pharmaceutical Product Development. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Regulatory Affairs Outsourcing Market Overview Chapter 4 Global Regulatory Affairs Outsourcing Market, by Services Chapter 5 Global Regulatory Affairs Outsourcing Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Accell Clinical Research, LLC - Charles River Laboratories International, Inc. - Clinilabs, Inc. - Covance, Inc. - Criterium, Inc. - ICON plc - Medpace, Inc. - PAREXEL International Corporation - PRA International, Inc. - Pharmaceutical Product Development, LLC - Promedica International - Quintiles Transnational Corporation - WuXi AppTec For more information visit http://www.researchandmarkets.com/research/8t6h79/regulatory
PRXL: 54.78 (+0.28), CRL: 64.08 (+0.15), ICLR: 53.37 (+0.03), CVD: 100.42 (-0.45)
Charles River Laboratories Earnings In Retrospect: Down 1.7% in the Last 12 Days (CRL)
Comtex SmarTrend(R) - Mon Nov 10, 9:16AM CST
A week ago on October 29th, 2014 Charles River Laboratories (NYSE:CRL) reported earnings and analysts, on average, expected earnings of $0.80 on sales of $326.8 million. The company actually reported EPS of $0.86 on sales of $327.6 million, beating EPS estimates by $0.06 and beating revenue estimates by $0.8 million. Shares of Charles River Laboratories have slipped from $64.47 to $63.36, representing a loss of 1.7%, since the company reported earnings 12 days ago.
CRL: 64.08 (+0.15)
Strength Seen in Covance (CVD): Stock Surges 25.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:25AM CST
Covance (CVD) was a big mover last session, with shares surging nearly 26% on the day.
BEAT: 8.22 (+0.02), CRL: 64.08 (+0.15), ICLR: 53.37 (+0.03), CVD: 100.42 (-0.45)
Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX
at The Street - Fri Oct 31, 5:00AM CDT
Cramer says Take-Two Interactive is king of the hill and he's a big fan of Flextronics and its stock buyback program.
FLEX: 10.93 (+0.19), TTWO: 26.09 (-0.01), BIIB: 323.95 (-3.92), GILD: 108.47 (+1.45), CRL: 64.08 (+0.15), REGN: 399.36 (+13.39), CELG: 107.55 (-0.46)
Cramer's Mad Money - Charles River Labs Battles Ebola (10/30/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Oct 31, 4:46AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday October 30. CEO Interview: James Foster, Charles River Labs (NYSE: CRL ) Cramer spoke with James Foster, CEO of Charles River Labs ( CRL ). The company...
FLEX: 10.93 (+0.19), MMM: 156.72 (-0.94), BIIB: 323.95 (-3.92), CLR: 54.83 (+0.61), HON: 96.81 (-0.46), FB: 74.36 (-0.64), DIS: 89.76 (-0.02), BMY: 58.69 (-0.12), CELG: 107.55 (-0.46), SBUX: 77.60 (-0.05), WWAV: 36.34 (+0.34), HAIN: 105.58 (-3.63), UA: 68.04 (-0.30), TTWO: 26.09 (-0.01), RDS.B: 74.45 (+0.28), RDS.A: 71.05 (+0.34), TJX: 63.22 (-0.70), GILD: 108.47 (+1.45), CMG: 654.12 (+5.26), COST: 136.69 (-1.00), BP: 41.83 (-0.03), ARCP: 8.67 (+0.17), CRL: 64.08 (+0.15), AAPL: 109.21 (+0.38), REGN: 399.36 (+13.39), WEN: 8.46 (-0.09)
Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong
at The Street - Thu Oct 30, 7:11PM CDT
The end of quantitative easing was supposed to create a laundry list of problems, Cramer says. It didn't happen.
MMM: 156.70 (-0.96), BIIB: 323.95 (-3.92), HON: 96.81 (-0.46), FB: 74.36 (-0.64), BMY: 58.70 (-0.11), MGM: 22.46 (+0.32), ATK: 111.44 (+1.18), YRCW: 24.40 (+0.10), UPS: 108.70 (-0.35), SLB: 98.19 (-0.10), CELG: 107.55 (-0.46), WPRT: 6.11 (+0.23), SBUX: 77.60 (-0.05), TTWO: 26.09 (-0.01), DO: 36.77 (-0.70), ETP: 64.93 (-0.44), GILD: 108.47 (+1.45), ARR: 3.98 (-0.01), CMG: 654.12 (+5.26), MPEL: 25.77 (+0.58), WNC: 10.75 (-0.01), CRL: 64.08 (+0.15), AAPL: 109.21 (+0.38), REGN: 399.36 (+13.39)
Charles River Laboratories International's (CRL) CEO James Foster on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 1:50PM CDT
CRL: 64.08 (+0.15)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 195.66 (+0.42), ABBV: 63.68 (-0.11), BMY: 58.70 (-0.11), CRL: 64.08 (+0.15)
Charles River Laboratories raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 9:53AM CDT
CRL: 64.08 (+0.15)
Charles River Laboratories International In (CRL) Falls Further As It's Water-Logged And Getting Wetter
at The Street - Thu Oct 30, 9:04AM CDT
Trade-Ideas LLC identified Charles River Laboratories International In (CRL) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
CRL: 64.08 (+0.15)
Charles River beats Street 3Q forecasts
Automated Insights - Wed Oct 29, 5:45PM CDT
WILMINGTON, Mass. (AP) _ Charles River Laboratories International Inc. (CRL) on Wednesday reported third-quarter earnings of $32 million.
CRL: 64.08 (+0.15)
Ampersand Exits ChanTest Investment
PR Newswire - Wed Oct 29, 3:56PM CDT
Ampersand Capital Partners is pleased to announce the successful sale of Cleveland, Ohio based ChanTest, a leading provider of specialized laboratory testing services for drug development. ChanTest has been acquired by Charles River Laboratories International, Inc. in an all-cash transaction.
CRL: 64.08 (+0.15)
Charles River Laboratories beats by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 3:30PM CDT
CRL: 64.08 (+0.15)
Charles River Laboratories Announces Third-Quarter 2014 Results from Continuing Operations
Business Wire - Wed Oct 29, 3:06PM CDT
--- Third-Quarter GAAP Earnings per Share of $0.68 and Non-GAAP Earnings per Share of $0.86 -
CRL: 64.08 (+0.15)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 195.66 (+0.42), ESRX: 77.70 (-0.29), CAH: 79.62 (+0.53), UNH: 95.61 (+0.86), CRL: 64.08 (+0.15)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 195.66 (+0.42), MCK: 202.49 (+1.21), CAH: 79.62 (+0.53), CRL: 64.08 (+0.15)
Will Cigna's (CI) Business Diversity Drive Q3 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:01PM CDT
We expect Cigna (CI) to give a positive surprise when it reports its earnings on Oct 30, given its Zacks Rank #3 and a positive Earnings ESP.
CI: 101.97 (+0.69), INFI: 13.65 (+0.08), AMAG: 34.92 (+0.01), CRL: 64.08 (+0.15)
Will PerkinElmer (PKI) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 4:59PM CDT
PerkinElmer (PKI) has managed to perform decently across several product lines and also posted solid operating results in the previous quarter.
HTWR: 79.14 (+0.53), CRL: 64.08 (+0.15), HSIC: 129.29 (-0.33), PKI: 43.79 (-0.23)
Notable earnings after Wednesday’s close
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:35PM CDT
CSGP: 159.96 (-0.02), CNW: 46.12 (-0.23), ACMP: 62.11 (-0.53), BGC: 13.98 (-0.07), DAC: 6.24 (-0.04), AIZ: 67.73 (-0.27), AEM: 24.16 (+1.15), ESRT: 15.96 (-0.06), CAR: 57.65 (-0.32), CWT: 25.39 (-0.24), AHL: 43.29 (-0.26), CLUB: 6.13 (-0.64), CAVM: 52.44 (-0.16), CJES: 18.86 (-0.06), FB: 74.36 (-0.64), AKAM: 60.98 (-0.09), EXR: 58.50 (-0.15), DWA: 21.89 (-0.20), EXL: 12.92 (-0.10), ANIK: 41.45 (+0.54), CLD: 12.98 (-0.05), ALL: 66.62 (-0.14), DRIV: 24.52 (-0.25), EQIX: 222.21 (+4.18), ESV: 39.39 (-0.53), ASGN: 30.03 (+0.01), AUY: 3.92 (+0.26), ACHC: 61.05 (-0.24), CALX: 11.33 (-0.05), CSII: 29.89 (-0.13), AFOP: 13.70 (unch), ARAY: 7.02 (+0.12), AEGN: 19.46 (-0.36), ATML: 7.56 (-0.04), CENX: 27.41 (+0.09), CUZ: 12.83 (-0.17), CACI: 85.37 (+1.45), ACGL: 57.21 (-0.05), AXS: 49.17 (-0.05), BMR: 21.58 (-0.07), ARII: 68.17 (-0.91), CBG: 32.47 (+0.66), CW: 70.66 (+0.10), DRE: 19.66 (+0.07), ABX: 11.75 (+0.40), CBL: 18.98 (-0.42), CHDN: 104.33 (-0.10), CMO: 12.63 (-0.03), CATM: 38.11 (+0.19), BLKB: 44.19 (-0.56), BIDU: 248.04 (+0.46), EQY: 24.15 (unch), ARRS: 28.69 (-1.77), ALDW: 18.73 (-0.51), CRUS: 19.57 (-0.12), CEMP: 14.13 (+0.33), CRL: 64.08 (+0.15)
Why Earnings Season Could Be Great for Charles River Laboratories International (CRL) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:57AM CDT
Investors are always looking for stocks that are poised to beat at earnings season and Charles River Laboratories International may be one such company as the firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report
CRL: 64.08 (+0.15)
